miRNA-142-5p和RPN2在胶质瘤中的表达及临床意义

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (618 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the expression and clinical significance of microRNA (miRNA)-142-5p and ribophorin 2 (RPN2) in glioma. Methods Eighty-five glioma patients treated in Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from January to December 2017 were selected. The expressions of miRNA-142-5p and RPN2 mRNA of cancer tissue and adjacent normal tissue were detected by qRT-PCR, the expression of RPN2 protein was detected by Western blot. Bioinformatics software and luciferase experiment were used to predict the interaction site between miRNA-142-5p and RPN2. The relationship between clinicopathological parameters and prognosis of patients with glioma and two indexes were analyzed. Results Compared with adjacent normal tissue, the expression of miRNA-142-5p was lower in cancer tissue, while the expressions of RPN2 mRNA and RPN2 protein were higher in cancer tissue (P < 0.05). There was negative correlation between miRNA-142-5p and RPN2 expression in cancer tissue (r = -0.604, P < 0.001). There were binding sites between miRNA-142-5p and RPN2 mRNA, compared with RPN2 WT group and RPN2 MUT+miRNA-142-5p mimic group, the luciferase activity of RPN2 WT+miRNA-142-5p mimic group was reduced (P < 0.05). The expressions of miRNA-142-5p and RPN2 mRNA were different in glioma patients with different Karnofsky performance status scores and World Health Organization grades (P < 0.05). In the cancer tissue group, patients with low expression of miRNA-142-5p and patients with high expression of RPN2 had a shorter median survival time than patients with high expression of miRNA-142-5p and patients with low expression of RPN2 (P < 0.05). Conclusion The expression of miRNA-142-5p is low and RPN2 is high in glioma. The expression of miRNA-142-5p and RPN2 is significantly negatively correlated, they are markers of poor survival and prognosis.

Key words： Glioma MiRNA-142-5p Ribophorin 2 Prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SU Jing ZHAO Jun LIANG Qiong

Cite this article:

SU Jing ZHAO Jun LIANG Qiong. Expression and clinical significance of miRNA-142-5p and RPN2 in glioma[J]. 中国医药导报, 2022, 19(20): 108-111.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I20/108

[1] 魏炜，刘振宇，田捷.影像组学在胶质瘤临床诊疗中的应用现状[J].中国微侵袭神经外科杂志，2018，23（6）：277-280.
[2] 刘宝辉，孙前，袁凡恩，等.高级别胶质瘤的治疗进展[J].中国临床神经外科杂志，2021，26（5）：380-384.
[3] 李乾，姜福金，温儒民，等.血浆miRNA-21和miRNA-142-5p表达水平对肾细胞癌的诊断价值评价[J].中国医药导报，2018，15（21）：4-7，18.
[4] 吕园，徐娟，邱樊，等.甲状腺乳头状癌miRNA差异表达谱分析[J].中华肿瘤防治杂志，2019，26（6）：389-394.
[5] 王庆宇，林菲菲，陈高扬，等.滑膜肉瘤差异表达基因生物信息学分析[J].中国体视学与图像分析，2018，23（3）：260-270.
[6] 赵征，张克难，孙思，等.核糖体结合糖蛋白2在脑胶质瘤中的表达及其在预后评估中的作用[J].中华神经外科杂志，2018，34（11）：1155-1160.
[7] 张好良，蔡晨晨，张苗苗，等.血清外泌体源性长链非编码RNA RP N2-4在胃癌中的表达及其筛查价值[J].临床检验杂志，2019，37（5）：331-333.
[8] 答秀维，张蓓，尚芸，等.RPN2与肝癌患者预后及对肝癌细胞生长的作用[J].现代生物医学进展，2020，20（8）：1425-1430.
[9] Sun J，Ma Q，Li B，et al. RPN2 is targeted by miRNA-181c and mediates glioma progression and temozolomide sensitivity via the wnt/β-catenin signaling pathway [J]. Cell Death Dis，2020，11（10）：890-897.
[10] 苗素平，郭二亮，裴荣，等.miRNA调节免疫检查点在肿瘤治疗中的研究进展[J].实用肿瘤学杂志，2018，32（1）：57-62.
[11] 武伦，汤志刚，李生伟，等.外泌体miRNA在肿瘤进展中的作用及其可能机制[J].中华肝脏病杂志，2021，29（9）：908-912.
[12] 李乐璇，张苗，邹军.MiRNA介导circRNA调控肿瘤的发展[J].中国细胞生物学学报，2021，43（1）：125-133.
[13] 谈胤求,陈谦学.外泌体在脑胶质瘤中的研究进展[J].疑难病杂志，2021，20（7）：731-735.
[14] 王鸿利，何琴，刘帆，等.miR-145-5p通过靶向DUSP6抑制LPS诱导的血管内皮细胞氧化损伤和炎症[J].中国免疫学杂志，2021，37（20）：2457-2461.
[15] 武磊，周文勤，袁琳楠，等.miR-145-5p靶向ARK5调控人上皮性卵巢癌细胞增殖凋亡的作用[J].中国医学科学院学报，2021，43（5）：669-676.
[16] 张雨薇，张馨月，白立川，等.ceRNA调控miR-145-5p介导肿瘤发生发展的研究进展[J].现代肿瘤医学，2020， 28（10）：1766-1769.
[17] Yao R，Xu L，Wei B，et al. miRNA-142-5p regulates pancreatic cancer cell proliferation and apoptosis by regulation of RAP1A [J]. Pathol Res Pract，2019，215（6）：152-164.
[18] Li M，Cai O，Tan S. LOXL1-AS1 drives the progression of gastric cancer via regulating miRNA-142-5p/PIK3CA axis [J]. Onco Targets Ther，2019，12（4）：11345-11357.
[19] Zhang H，Ma H，Zhang W，et al. Increased expression of Sema3C indicates a poor prognosis and is regulated by miRNA-142-5p in glioma [J]. Biol Pharm Bull，2020，43（4）：639-648.
[20] Ren J，Wang Y，Wang L，et al. Ribophorin Ⅱ is upregulated in myelodysplastic syndromes and prevents apoptosis and cell cycle progression [J]. Exp Biol Med （Maywood），2020，245（12）：1009-1015.
[21] Hemmis CW，Heard SC，Hill CP. Phosphorylation of Tyr-950 in the proteasome scaffolding protein RPN2 modulates its interaction with the ubiquitin receptor RPN13 [J]. J Biol Chem，2019，294（25）：9659-9665.
[22] Bi C，Jiang B. Downregulation of RPN2 induces apoptosis and inhibits migration and invasion in colon carcinoma [J]. Oncol Rep，2018，40（1）：283-293.
[23] Li H，Al-Japairai K，Tao Y，et al. RPN2 promotes colorectal cancer cell proliferation through modulating the glycosylation status of EGFR [J]. Oncotarget，2017，8（42）：72633-72651.
[24] Zhang H，Jiang H，Zhang H，et al. Ribophorin Ⅱ potentiates P-glycoprotein- and ABCG2-mediated multidrug resistance via activating ERK pathway in gastric cancer [J]. Int J Biol Macromol，2019，128（5）：574-582.
[25] Zhou T，Wu L，Wang Q，et al. MicroRNA-128 targeting RPN2 inhibits cell proliferation and migration through the Akt-p53-cyclin pathway in colorectal cancer cells [J]. Oncol Lett，2018，16（6）：6940-6949.
[26] Ou ZL，Zhang M，Ji LD，et al. Long noncoding RNA FEZF1-AS1 predicts poor prognosis and modulates pancreatic cancer cell proliferation and invasion through miRNA-142/HIF-1α and miRNA-133a/EGFR upon hypoxia/normoxia [J]. J Cell Physiol，2019，28（4）：147-152.